Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;182(2):511-512.
doi: 10.1007/s10549-020-05694-3. Epub 2020 May 26.

Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID‑19 pandemic. The COVID‑19 pandemic breast cancer consortium"

Peter Beitsch  1 , Pat Whitworth  2 , Rakesh Patel  3
Affiliations
Comment

Response to the article by Dietz et al. entitled "Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID‑19 pandemic. The COVID‑19 pandemic breast cancer consortium"

Peter Beitsch et al. Breast Cancer Res Treat. 2020 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Whitworth P, Stork-Sloots L, de Snoo FA, et al. Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Ann Surg Oncol. 2014;21(10):3261–3267. doi: 10.1245/s10434-014-3908-y. - DOI - PMC - PubMed
    1. Beitsch P, Whitworth P, Baron P, et al. Pertuzumab/trastuzumab/CT versus trastuzumab/CT therapy for HER2+ breast cancer: results from the prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Ann Surg Oncol. 2017;24(9):2539–2546. doi: 10.1245/s10434-017-5863-x. - DOI - PubMed
    1. Pease AM, Riba LA, Gruner RA, et al. Oncotype DX recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(2):366–371. doi: 10.1245/s10434-018-07107-8. - DOI - PubMed